The best dental leads don't come through the dentist. Distributors keep missing that.

Most dental manufacturers and their distributors share one quiet assumption: demand starts in the chair. A dentist decides a patient needs an implant, an aligner, a membrane — and somewhere upstream, a distributor takes the order. The whole industry is built around selling to the practitioner.

I spent part of my career on the other side of that assumption — working with one of the industry's largest producers and building direct-to-consumer brands on top of what had always been B2B products, creating patient demand that did not originate with the dentist at all. On the education side of the same channel, I've worked on marketing and sales training for dentists with the professional dental association in Switzerland and alongside the Swiss dental hygienists' association.

What the aligner wave actually proved

The outline is public. The industry's biggest implant producer — the epitome of B2B dental — took a majority stake in a direct-to-consumer aligner brand in 2020, built it into one of Europe's category leaders, and passed it on in 2024 while keeping a stake in the combined business. Strategies evolve; portfolios get reshuffled. But the mechanic that made it work hasn't gone anywhere.

That mechanic: a patient searches for a better smile, not for a SKU. A consumer brand catches that search, builds trust, qualifies the lead — and then hands a motivated, pre-educated patient to a practitioner. The doctor stays in charge of the treatment. What changes is who created the demand.

Once you've run that model, you can't unsee what it does to the relationships. The patient trusts the brand before they've met the doctor. New products get easier to introduce to practitioners, because you're no longer pitching a catalogue item — you're bringing them patients who already want the outcome. And the practice gets a revenue stream it never had to market for.

A distributor that generates patient demand stops being a middleman and starts being a market maker.

Why this matters for distributors, not just manufacturers

European dental distribution is mostly an order-taking business. The distributor holds the relationship with the dentist, carries the stock, does the training — and waits for demand to show up. Meanwhile the European implant market grows at a steady seven-plus percent a year, and nearly all of that growth is fought over inside the clinic, on margin and on service level.

The categories that grew fastest in the last decade — aligners, aesthetic treatments, consumer-grade healthcare experiences — didn't grow because dentists ordered more. They grew because someone built brands that made patients ask for them. I wrote about that dynamic in the high-stakes art of selling a smile: the moment a treatment becomes something a person wants rather than something a clinician prescribes, the economics of the whole channel change.

For a distributor, that's not a threat. It's the most defensible move available. You already have what a pure D2C player has to buy expensively: clinical relationships, logistics, regulatory know-how, and the trust of the practitioners who will ultimately deliver the treatment. What's missing is the demand engine — patient-facing brand, localized landing pages, performance marketing, lead qualification, and a clean handover into the practices you already serve.

The guardrails that keep it honest

This only works doctor-led. The model that succeeded kept licensed dentists in every treatment decision, and in Europe that isn't optional: medical-device advertising rules, country-by-country claim restrictions, and professional codes all apply the moment you talk to patients. The demand engine has to sell the outcome and route to a clinician — never play clinician itself.

And it only works if the practitioner wins visibly. The fastest way to poison a distribution network is to make dentists feel disintermediated. The design goal is the opposite: every lead the brand generates lands in a partner practice, attributed, qualified, and free of acquisition cost for the dentist. Do that, and the same practices that used to see you as a supplier start seeing you as the reason their chairs are full.

None of this requires a big team. It requires someone who has pulled these levers before — brand, regulated performance marketing, lead routing — and the judgement to know which lever matters in which market. That's exactly the kind of work I keep coming back to in my fractional executive practice: not more headcount, just the right reps applied at the right layer of the channel.

The dentist will always own the treatment. But whoever owns the demand owns the growth.

Sources & further reading

External:
The 2020 majority stake in a D2C aligner brand (Wikipedia)
The 2024 divestiture in return for a minority stake (Dental Tribune)
Europe dental implants market outlook (Mordor Intelligence)
Swiss dental association · Swiss dental hygienists' association

Related posts:
Where the European dental industry actually meets — a distributor's calendar
The high-stakes art of selling a smile
The boutique-hotel-ification of healthcare
What does a fractional CMO do?